Avalanche Biotechnologies, an early-stage biotech developing a gene therapy for wet AMD, raised $102 million by offering 6.0 million shares at $17, the high end of its upwardly revised $16 to $17 range. The company originally filed to offer 5.4 million shares at $13 to $15 before increasing its range in an amendment filed on Wednesday. Avalanche Biotechnologies will list on the NASDAQ under the symbol AAVL. Jefferies, Cowen & Company and Piper Jaffray acted as joint bookrunners on the deal.
